Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours
Background Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood–brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in t...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2020-11, Vol.123 (11), p.1633-1643 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1643 |
|---|---|
| container_issue | 11 |
| container_start_page | 1633 |
| container_title | British journal of cancer |
| container_volume | 123 |
| creator | Nonaka, Motohiro Suzuki-Anekoji, Misa Nakayama, Jun Mabashi-Asazuma, Hideaki Jarvis, Donald L. Yeh, Jiunn-Chern Yamasaki, Kazuhiko Akama, Tomoya O. Huang, Chun-Teng Campos, Alexandre Rosa Nagaoka, Masato Sasai, Toshio Kimura-Takagi, Itsuko Suwa, Yoichi Yaegashi, Takashi Shibata, Toshiaki K. Sugihara, Kazuhiro Nishizawa-Harada, Chizuko Fukuda, Minoru Fukuda, Michiko N. |
| description | Background
Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood–brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in the mouse.
Methods
(1) A dual-tumour model was generated by inoculating luciferase-expressing melanoma B16 cell line, B16-Luc, into the brain and under the skin of syngeneic C57BL/6 mice. IF7C(RR)-SN38 was injected intravenously daily at 7.0 μmoles/kg and growth of tumours was assessed by chemiluminescence using an IVIS imager. A similar dual-tumour model was generated with the C6-Luc line in immunocompromised SCID mice. (2) IF7C(RR)-SN38 formulated with 10% Solutol HS15 was injected intravenously daily at 2.5 μmoles/kg into two brain tumour mouse models: B16-Luc cells in C57BL/6 mice, and C6-Luc cells in nude mice.
Results
(1) Daily IF7C(RR)-SN38 injection suppressed tumour growth regardless of cell lines or mouse strains. (2) Daily injection of Solutol-formulated IF7C(RR)-SN38 led into complete disappearance of B16-Luc brain tumour in C57BL/6 mice, whereas this did not occur in C6-Luc in nude mice.
Conclusions
IF7C(RR)-SN38 crosses the blood–brain barrier and suppresses growth of brain tumours in mouse models. Solutol HS15-formulated IF7C(RR)-SN38 may have promoted an antitumour immune response. |
| doi_str_mv | 10.1038/s41416-020-01066-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7686308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473218639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ee30226ae22d540440368798dc8b486d70611fbcc38e1da1da634b66cc6d0ef03</originalsourceid><addsrcrecordid>eNp9kc1qFTEYhoNY7LF6Ay5kwI2b2C8_J8lshEPxDwrd1I2bkEm-czplJjkmM6XdeQ_eoVdi6tT6sygEQvI975u8vIS8YPCGgTDHRTLJFAUOFBgoRfkjsmJrwSkzXD8mKwDQFFoOh-RpKZf12ILRT8ih4C1nuuUr8uXsCrNPYx93zXSBTTekFH58-95l18emczn3mJvuptnEiNf1asNo18dwy-9xP_UBmyk1k8s7nJpFNc1jmnN5Rg62bij4_G4_Ip_fvzs_-UhPzz58OtmcUi-1nCiiAM6VQ87DWoKUIJTRrQnedNKooEExtu28FwZZcHUpITulvFcBcAviiLxdfPdzN2LwGKfsBrvP_ejyjU2ut_9OYn9hd-nKamWUAFMNXt8Z5PR1xjLZsS8eh8FFTHOxXEq-btvKVvTVf-hljRprvEppwVl1bCvFF8rnVErG7f1nGNjb6uxSna3V2V_VWV5FL_-OcS_53VUFxAKUOoo7zH_efsD2J7zvpb8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473218639</pqid></control><display><type>article</type><title>Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nonaka, Motohiro ; Suzuki-Anekoji, Misa ; Nakayama, Jun ; Mabashi-Asazuma, Hideaki ; Jarvis, Donald L. ; Yeh, Jiunn-Chern ; Yamasaki, Kazuhiko ; Akama, Tomoya O. ; Huang, Chun-Teng ; Campos, Alexandre Rosa ; Nagaoka, Masato ; Sasai, Toshio ; Kimura-Takagi, Itsuko ; Suwa, Yoichi ; Yaegashi, Takashi ; Shibata, Toshiaki K. ; Sugihara, Kazuhiro ; Nishizawa-Harada, Chizuko ; Fukuda, Minoru ; Fukuda, Michiko N.</creator><creatorcontrib>Nonaka, Motohiro ; Suzuki-Anekoji, Misa ; Nakayama, Jun ; Mabashi-Asazuma, Hideaki ; Jarvis, Donald L. ; Yeh, Jiunn-Chern ; Yamasaki, Kazuhiko ; Akama, Tomoya O. ; Huang, Chun-Teng ; Campos, Alexandre Rosa ; Nagaoka, Masato ; Sasai, Toshio ; Kimura-Takagi, Itsuko ; Suwa, Yoichi ; Yaegashi, Takashi ; Shibata, Toshiaki K. ; Sugihara, Kazuhiro ; Nishizawa-Harada, Chizuko ; Fukuda, Minoru ; Fukuda, Michiko N.</creatorcontrib><description>Background
Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood–brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in the mouse.
Methods
(1) A dual-tumour model was generated by inoculating luciferase-expressing melanoma B16 cell line, B16-Luc, into the brain and under the skin of syngeneic C57BL/6 mice. IF7C(RR)-SN38 was injected intravenously daily at 7.0 μmoles/kg and growth of tumours was assessed by chemiluminescence using an IVIS imager. A similar dual-tumour model was generated with the C6-Luc line in immunocompromised SCID mice. (2) IF7C(RR)-SN38 formulated with 10% Solutol HS15 was injected intravenously daily at 2.5 μmoles/kg into two brain tumour mouse models: B16-Luc cells in C57BL/6 mice, and C6-Luc cells in nude mice.
Results
(1) Daily IF7C(RR)-SN38 injection suppressed tumour growth regardless of cell lines or mouse strains. (2) Daily injection of Solutol-formulated IF7C(RR)-SN38 led into complete disappearance of B16-Luc brain tumour in C57BL/6 mice, whereas this did not occur in C6-Luc in nude mice.
Conclusions
IF7C(RR)-SN38 crosses the blood–brain barrier and suppresses growth of brain tumours in mouse models. Solutol HS15-formulated IF7C(RR)-SN38 may have promoted an antitumour immune response.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-01066-2</identifier><identifier>PMID: 32921792</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1922 ; 692/699/67/1059 ; Animal models ; Animals ; Annexin A1 - metabolism ; Antineoplastic Agents - pharmacology ; Biomedical and Life Sciences ; Biomedicine ; Blood-brain barrier ; Blood-Brain Barrier - metabolism ; Brain cancer ; Brain Neoplasms ; Brain tumors ; Cancer Research ; Cell culture ; Chemiluminescence ; Drug Carriers - pharmacology ; Drug Resistance ; Epidemiology ; Humans ; Immune response ; Injection ; Melanoma ; Mice ; Mice, Inbred C57BL ; Mice, SCID ; Molecular Medicine ; Oncology ; Peptides ; Rats ; Tumor cell lines ; Tumors</subject><ispartof>British journal of cancer, 2020-11, Vol.123 (11), p.1633-1643</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ee30226ae22d540440368798dc8b486d70611fbcc38e1da1da634b66cc6d0ef03</citedby><cites>FETCH-LOGICAL-c474t-ee30226ae22d540440368798dc8b486d70611fbcc38e1da1da634b66cc6d0ef03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686308/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686308/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32921792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nonaka, Motohiro</creatorcontrib><creatorcontrib>Suzuki-Anekoji, Misa</creatorcontrib><creatorcontrib>Nakayama, Jun</creatorcontrib><creatorcontrib>Mabashi-Asazuma, Hideaki</creatorcontrib><creatorcontrib>Jarvis, Donald L.</creatorcontrib><creatorcontrib>Yeh, Jiunn-Chern</creatorcontrib><creatorcontrib>Yamasaki, Kazuhiko</creatorcontrib><creatorcontrib>Akama, Tomoya O.</creatorcontrib><creatorcontrib>Huang, Chun-Teng</creatorcontrib><creatorcontrib>Campos, Alexandre Rosa</creatorcontrib><creatorcontrib>Nagaoka, Masato</creatorcontrib><creatorcontrib>Sasai, Toshio</creatorcontrib><creatorcontrib>Kimura-Takagi, Itsuko</creatorcontrib><creatorcontrib>Suwa, Yoichi</creatorcontrib><creatorcontrib>Yaegashi, Takashi</creatorcontrib><creatorcontrib>Shibata, Toshiaki K.</creatorcontrib><creatorcontrib>Sugihara, Kazuhiro</creatorcontrib><creatorcontrib>Nishizawa-Harada, Chizuko</creatorcontrib><creatorcontrib>Fukuda, Minoru</creatorcontrib><creatorcontrib>Fukuda, Michiko N.</creatorcontrib><title>Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood–brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in the mouse.
Methods
(1) A dual-tumour model was generated by inoculating luciferase-expressing melanoma B16 cell line, B16-Luc, into the brain and under the skin of syngeneic C57BL/6 mice. IF7C(RR)-SN38 was injected intravenously daily at 7.0 μmoles/kg and growth of tumours was assessed by chemiluminescence using an IVIS imager. A similar dual-tumour model was generated with the C6-Luc line in immunocompromised SCID mice. (2) IF7C(RR)-SN38 formulated with 10% Solutol HS15 was injected intravenously daily at 2.5 μmoles/kg into two brain tumour mouse models: B16-Luc cells in C57BL/6 mice, and C6-Luc cells in nude mice.
Results
(1) Daily IF7C(RR)-SN38 injection suppressed tumour growth regardless of cell lines or mouse strains. (2) Daily injection of Solutol-formulated IF7C(RR)-SN38 led into complete disappearance of B16-Luc brain tumour in C57BL/6 mice, whereas this did not occur in C6-Luc in nude mice.
Conclusions
IF7C(RR)-SN38 crosses the blood–brain barrier and suppresses growth of brain tumours in mouse models. Solutol HS15-formulated IF7C(RR)-SN38 may have promoted an antitumour immune response.</description><subject>631/67/1922</subject><subject>692/699/67/1059</subject><subject>Animal models</subject><subject>Animals</subject><subject>Annexin A1 - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood-brain barrier</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Brain cancer</subject><subject>Brain Neoplasms</subject><subject>Brain tumors</subject><subject>Cancer Research</subject><subject>Cell culture</subject><subject>Chemiluminescence</subject><subject>Drug Carriers - pharmacology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Injection</subject><subject>Melanoma</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, SCID</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Peptides</subject><subject>Rats</subject><subject>Tumor cell lines</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1qFTEYhoNY7LF6Ay5kwI2b2C8_J8lshEPxDwrd1I2bkEm-czplJjkmM6XdeQ_eoVdi6tT6sygEQvI975u8vIS8YPCGgTDHRTLJFAUOFBgoRfkjsmJrwSkzXD8mKwDQFFoOh-RpKZf12ILRT8ih4C1nuuUr8uXsCrNPYx93zXSBTTekFH58-95l18emczn3mJvuptnEiNf1asNo18dwy-9xP_UBmyk1k8s7nJpFNc1jmnN5Rg62bij4_G4_Ip_fvzs_-UhPzz58OtmcUi-1nCiiAM6VQ87DWoKUIJTRrQnedNKooEExtu28FwZZcHUpITulvFcBcAviiLxdfPdzN2LwGKfsBrvP_ejyjU2ut_9OYn9hd-nKamWUAFMNXt8Z5PR1xjLZsS8eh8FFTHOxXEq-btvKVvTVf-hljRprvEppwVl1bCvFF8rnVErG7f1nGNjb6uxSna3V2V_VWV5FL_-OcS_53VUFxAKUOoo7zH_efsD2J7zvpb8</recordid><startdate>20201124</startdate><enddate>20201124</enddate><creator>Nonaka, Motohiro</creator><creator>Suzuki-Anekoji, Misa</creator><creator>Nakayama, Jun</creator><creator>Mabashi-Asazuma, Hideaki</creator><creator>Jarvis, Donald L.</creator><creator>Yeh, Jiunn-Chern</creator><creator>Yamasaki, Kazuhiko</creator><creator>Akama, Tomoya O.</creator><creator>Huang, Chun-Teng</creator><creator>Campos, Alexandre Rosa</creator><creator>Nagaoka, Masato</creator><creator>Sasai, Toshio</creator><creator>Kimura-Takagi, Itsuko</creator><creator>Suwa, Yoichi</creator><creator>Yaegashi, Takashi</creator><creator>Shibata, Toshiaki K.</creator><creator>Sugihara, Kazuhiro</creator><creator>Nishizawa-Harada, Chizuko</creator><creator>Fukuda, Minoru</creator><creator>Fukuda, Michiko N.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201124</creationdate><title>Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours</title><author>Nonaka, Motohiro ; Suzuki-Anekoji, Misa ; Nakayama, Jun ; Mabashi-Asazuma, Hideaki ; Jarvis, Donald L. ; Yeh, Jiunn-Chern ; Yamasaki, Kazuhiko ; Akama, Tomoya O. ; Huang, Chun-Teng ; Campos, Alexandre Rosa ; Nagaoka, Masato ; Sasai, Toshio ; Kimura-Takagi, Itsuko ; Suwa, Yoichi ; Yaegashi, Takashi ; Shibata, Toshiaki K. ; Sugihara, Kazuhiro ; Nishizawa-Harada, Chizuko ; Fukuda, Minoru ; Fukuda, Michiko N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ee30226ae22d540440368798dc8b486d70611fbcc38e1da1da634b66cc6d0ef03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67/1922</topic><topic>692/699/67/1059</topic><topic>Animal models</topic><topic>Animals</topic><topic>Annexin A1 - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood-brain barrier</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Brain cancer</topic><topic>Brain Neoplasms</topic><topic>Brain tumors</topic><topic>Cancer Research</topic><topic>Cell culture</topic><topic>Chemiluminescence</topic><topic>Drug Carriers - pharmacology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Injection</topic><topic>Melanoma</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, SCID</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Peptides</topic><topic>Rats</topic><topic>Tumor cell lines</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nonaka, Motohiro</creatorcontrib><creatorcontrib>Suzuki-Anekoji, Misa</creatorcontrib><creatorcontrib>Nakayama, Jun</creatorcontrib><creatorcontrib>Mabashi-Asazuma, Hideaki</creatorcontrib><creatorcontrib>Jarvis, Donald L.</creatorcontrib><creatorcontrib>Yeh, Jiunn-Chern</creatorcontrib><creatorcontrib>Yamasaki, Kazuhiko</creatorcontrib><creatorcontrib>Akama, Tomoya O.</creatorcontrib><creatorcontrib>Huang, Chun-Teng</creatorcontrib><creatorcontrib>Campos, Alexandre Rosa</creatorcontrib><creatorcontrib>Nagaoka, Masato</creatorcontrib><creatorcontrib>Sasai, Toshio</creatorcontrib><creatorcontrib>Kimura-Takagi, Itsuko</creatorcontrib><creatorcontrib>Suwa, Yoichi</creatorcontrib><creatorcontrib>Yaegashi, Takashi</creatorcontrib><creatorcontrib>Shibata, Toshiaki K.</creatorcontrib><creatorcontrib>Sugihara, Kazuhiro</creatorcontrib><creatorcontrib>Nishizawa-Harada, Chizuko</creatorcontrib><creatorcontrib>Fukuda, Minoru</creatorcontrib><creatorcontrib>Fukuda, Michiko N.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nonaka, Motohiro</au><au>Suzuki-Anekoji, Misa</au><au>Nakayama, Jun</au><au>Mabashi-Asazuma, Hideaki</au><au>Jarvis, Donald L.</au><au>Yeh, Jiunn-Chern</au><au>Yamasaki, Kazuhiko</au><au>Akama, Tomoya O.</au><au>Huang, Chun-Teng</au><au>Campos, Alexandre Rosa</au><au>Nagaoka, Masato</au><au>Sasai, Toshio</au><au>Kimura-Takagi, Itsuko</au><au>Suwa, Yoichi</au><au>Yaegashi, Takashi</au><au>Shibata, Toshiaki K.</au><au>Sugihara, Kazuhiro</au><au>Nishizawa-Harada, Chizuko</au><au>Fukuda, Minoru</au><au>Fukuda, Michiko N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2020-11-24</date><risdate>2020</risdate><volume>123</volume><issue>11</issue><spage>1633</spage><epage>1643</epage><pages>1633-1643</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood–brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in the mouse.
Methods
(1) A dual-tumour model was generated by inoculating luciferase-expressing melanoma B16 cell line, B16-Luc, into the brain and under the skin of syngeneic C57BL/6 mice. IF7C(RR)-SN38 was injected intravenously daily at 7.0 μmoles/kg and growth of tumours was assessed by chemiluminescence using an IVIS imager. A similar dual-tumour model was generated with the C6-Luc line in immunocompromised SCID mice. (2) IF7C(RR)-SN38 formulated with 10% Solutol HS15 was injected intravenously daily at 2.5 μmoles/kg into two brain tumour mouse models: B16-Luc cells in C57BL/6 mice, and C6-Luc cells in nude mice.
Results
(1) Daily IF7C(RR)-SN38 injection suppressed tumour growth regardless of cell lines or mouse strains. (2) Daily injection of Solutol-formulated IF7C(RR)-SN38 led into complete disappearance of B16-Luc brain tumour in C57BL/6 mice, whereas this did not occur in C6-Luc in nude mice.
Conclusions
IF7C(RR)-SN38 crosses the blood–brain barrier and suppresses growth of brain tumours in mouse models. Solutol HS15-formulated IF7C(RR)-SN38 may have promoted an antitumour immune response.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32921792</pmid><doi>10.1038/s41416-020-01066-2</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2020-11, Vol.123 (11), p.1633-1643 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7686308 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | 631/67/1922 692/699/67/1059 Animal models Animals Annexin A1 - metabolism Antineoplastic Agents - pharmacology Biomedical and Life Sciences Biomedicine Blood-brain barrier Blood-Brain Barrier - metabolism Brain cancer Brain Neoplasms Brain tumors Cancer Research Cell culture Chemiluminescence Drug Carriers - pharmacology Drug Resistance Epidemiology Humans Immune response Injection Melanoma Mice Mice, Inbred C57BL Mice, SCID Molecular Medicine Oncology Peptides Rats Tumor cell lines Tumors |
| title | Overcoming the blood–brain barrier by Annexin A1-binding peptide to target brain tumours |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A11%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overcoming%20the%20blood%E2%80%93brain%20barrier%20by%20Annexin%20A1-binding%20peptide%20to%20target%20brain%20tumours&rft.jtitle=British%20journal%20of%20cancer&rft.au=Nonaka,%20Motohiro&rft.date=2020-11-24&rft.volume=123&rft.issue=11&rft.spage=1633&rft.epage=1643&rft.pages=1633-1643&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-01066-2&rft_dat=%3Cproquest_pubme%3E2473218639%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473218639&rft_id=info:pmid/32921792&rfr_iscdi=true |